Literature DB >> 2245160

Morphine: pharmacokinetics and clinical practice.

P J Hoskin, G W Hanks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2245160      PMCID： PMC1971540          DOI： 10.1038/bjc.1990.363

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  24 in total

1.  Analgesic potency of normorphine in patients with postoperative pain.

Authors:  L LASAGNA; T J DE KORNFELD
Journal:  J Pharmacol Exp Ther       Date:  1958-11       Impact factor: 4.030

2.  Morphine-6-glucuronide, a potent mu agonist.

Authors:  G W Pasternak; R J Bodnar; J A Clark; C E Inturrisi
Journal:  Life Sci       Date:  1987-12-28       Impact factor: 5.037

3.  The morphine hydrogel suppository. A new sustained release rectal preparation.

Authors:  C D Hanning; A P Vickers; G Smith; N B Graham; M E McNeil
Journal:  Br J Anaesth       Date:  1988-08       Impact factor: 9.166

4.  Serum morphine concentrations after buccal and intramuscular morphine administration.

Authors:  A P Fisher; C Fung; M Hanna
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

5.  Explanation for potency of repeated oral doses of morphine?

Authors:  G W Hanks; P J Hoskin; G W Aherne; P Turner; P Poulain
Journal:  Lancet       Date:  1987-09-26       Impact factor: 79.321

6.  Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects.

Authors:  J X Mazoit; P Sandouk; P Zetlaoui; J M Scherrmann
Journal:  Anesth Analg       Date:  1987-04       Impact factor: 5.108

7.  Kinetics of morphine in patients with renal failure.

Authors:  J Säwe; I Odar-Cederlöf
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  The management of symptoms in advanced cancer: experience in a hospital-based continuing care unit.

Authors:  P J Hoskin; G W Hanks
Journal:  J R Soc Med       Date:  1988-06       Impact factor: 5.344

9.  Influence of pH on the buccal absorption of morphine sulphate and its major metabolite, morphine-3-glucuronide.

Authors:  O Al-Sayed-Omar; A Johnston; P Turner
Journal:  J Pharm Pharmacol       Date:  1987-11       Impact factor: 3.765

10.  Relative bioavailability of controlled release morphine tablets (MST continus) in cancer patients.

Authors:  P Poulain; P J Hoskin; G W Hanks; O A-Omar; V A Walker; A Johnston; P Turner; G W Aherne
Journal:  Br J Anaesth       Date:  1988-11       Impact factor: 9.166
View more
  4 in total

1.  Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients.

Authors:  T J Wilkinson; B A Robinson; E J Begg; S B Duffull; P J Ravenscroft; J J Schneider
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Morphine-6beta-glucuronide modulates the expression of inducible nitric oxide synthase.

Authors:  D T Lysle; K A Carrigan
Journal:  Inflammation       Date:  2001-08       Impact factor: 4.092

3.  Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide.

Authors:  D Hucks; P I Thompson; L McLoughlin; S P Joel; N Patel; A Grossman; L H Rees; M L Slevin
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

4.  A simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuse.

Authors:  Oscar B Torres; Joshua F G Antoline; Fuying Li; Rashmi Jalah; Arthur E Jacobson; Kenner C Rice; Carl R Alving; Gary R Matyas
Journal:  Anal Bioanal Chem       Date:  2015-12-16       Impact factor: 4.142
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.